Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | 3004299 | PO / MO |
The patient took Vivotif on 04-Jun-2025, second dose on 06-Jun-2025 and third dose on 11-Jun-2025; Case reference number US-BN-2025-001055 is a spontaneous case initially received from a nurse via Communications (reference number: USBAV25-1377) on 11-Jun-2025 and concerns 67-years-old female patient. The patient's medical history included Asthma. The patient's concomitant medications were not provided. On 04-Jun-2025, the patient took first dose of Vivotif, (batch number: 3004299) at unknown dose, orally for indication travel. On 06-Jun-2025, the patient took second dose of Vivotif, (batch number: 3004299) at unknown dose, orally. On 11-Jun-2025, the patient took third dose of Vivotif, (batch number: 3004299) at unknown dose, orally (explicitly coded as 'Inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information reported.; Reporter's Comments: A spontaneous case concerning, a 67-year-old female patient took three oral doses of Vivotif , with the third dose coded as "inappropriate schedule." The vaccine doses were administered at unknown strengths. At the time of reporting, no adverse events were known. Medical history included asthma; no concomitant medications were reported. The event is listed as per company conventions. Event inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A spontaneous case concerning, a 67-year-old female patient took three oral doses of Vivotif , with the third dose coded as "inappropriate schedule." The vaccine doses were administered at unknown strengths. At the time of reporting, no adverse events were known. Medical history included asthma; no concomitant medications were reported. The event is listed as per company conventions. Event inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Medical History/Concurrent Conditions: Asthma